Search global stocks & ETFs...Ctrl K

Learn Mode

HALO - Halozyme Therapeutics Inc

156

$69.21

-$0.82 (-1.171%)

At market close

$68.48

-$0.73 (-1.061%)

Pre Market 5/15/26, 11:26 AM

Score

4.33/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

HALO

Valuation Score

View as %

Stock Unlock

YTD

Max

Stock Profile

Market Cap

$8.21B

Industry

Biotechnology

EPS (TTM)

$2.69

P/E (TTM)

25.91

Div & Yield

FCF Payout Ratio

P/S (TTM)

5.88

P/B

168.17

Diluted Shares

117.65M

Ex-Dividend

Next Earnings

08-03

Forward P/E

7.91

Payout Ratio

P/FCF (TTM)

23.01

FCF Yield

4.35%

Earnings Yield

3.86%

52 Week Range

Score Card

Explore Scores Tab

4.33

Very Good

Halozyme Therapeutics Inc has grown revenue at 37.55% over the past year, which is strong growth. Also, it has a free cash flow margin of 25.55%, which suggests the company is very profitable.

Valuation Model

Key Score

4.00

Good

Management

3.00

Average

Growth

5.00

Very Good

Profitability

3.00

Average

Fin. Health

3.00

Average

Dividends

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

4 new filings were in the last 7 days

Filter Form Types

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-13 17:50:19

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-11 16:10:16

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-11 16:09:29

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-11 16:06:06

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 19:04:36

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 19:04:01

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 19:03:43

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 19:02:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 19:02:11

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-07 19:01:36

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 16:16:24

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-05 17:05:10

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$100.80

45.6%

Avg:

$86.93

25.6%

Low:

$57.57

-16.8%

(% change is relative to the current stock price: $69.21)

Analyst Recommendations

Go to Analyst Tab

3.80

Good

13%

Strong Buy (2)

60%

Buy (9)

20%

Hold (3)

Sell (1)

Strong Sell (0)

About

Website
https://www.halozyme.com/
Address
12390 El Camino Real, San Diego CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1159036

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. The company is headquartered in San Diego, California and currently employs 423 full-time employees. The company went IPO on 2003-01-30. The firm's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The firm licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. The company also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The firm has two commercial proprietary products, Hylenex and XYOSTED. The company also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

IPO Date

2003-01-30

Industry

Biotechnology

Total Employees

423

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences

HALO - Halozyme Therapeutics Inc

156

$69.21

-$0.82 (-1.171%)

$68.48

-$0.73 (-1.061%)

4.33/5

Stock Unlock

Stock Profile

Score Card

Very Good

Insider Transactions

Market News

Form 4

Filed on 2026-05-13 17:50:19

Form 144

Filed on 2026-05-11 16:10:16

Form 10-Q

Filed on 2026-05-11 16:09:29

Form 8-K

Filed on 2026-05-11 16:06:06

Form 4

Filed on 2026-05-07 19:04:36

Form 4

Filed on 2026-05-07 19:04:01

Form 4

Filed on 2026-05-07 19:03:43

Form 4

Filed on 2026-05-07 19:02:55

Form 4

Filed on 2026-05-07 19:02:11

Form 4

Filed on 2026-05-07 19:01:36

Form 8-K

Filed on 2026-05-07 16:16:24

Form 4

Filed on 2026-05-05 17:05:10

Financials

Price Targets

45.6%

25.6%

-16.8%

Analyst Recommendations

About

Similar Stocks